SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: erippetoe who wrote (63200)7/28/2025 5:04:59 PM
From: Olecranon3 Recommendations

Recommended By
bodish
erippetoe
jhcimmu

   of 63276
 
US FDA recommends removal of hold on Sarepta's Elevidys in some patients

Reuters 2025-07-28T16:56:00-04:00
July 28 (Reuters) - The U.S. Food and Drug Administration said on Monday it is recommending the removal of the hold placed on Sarepta Therapeutics'(SRPT.NaE) gene therapy Elevidys for patients with a rare muscular disorder who can walk.

The FDA's recommendation followed a probe that showed the death of an

8 year old boy

was unrelated to the gene therapy for Duchenne Muscular Dystrophy, the agency said.

(Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News